CORONARY ARTERY DISEASE - SECONDARY PREVENTION

0076 Optimal vascular care
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0073 IVD: blood pressure management
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0068 IVD: use of aspirin or another antithrombotic
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0067 CAD: antiplatlet therapy
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0075 IVD- complete lipid profile and LDL control <100
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0074 Chronic stable coronary artery disease: lipid control
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure

0066 Chronic stable coronary artery disease: ACE inhibitor or ARB therapy—diabetes or left ventricular systolic dysfunction (LVEF < 40%)
  ______ I approve the measure currently specified
  ______ I disapprove the measure currently specified
  ______ I abstain from voting on this measure
0070 Chronic Stable Coronary Artery Disease: Beta-Blocker Treatment – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF<40%)

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

0071 AMI: Persistence of beta blocker therapy after a heart attack

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

CORONARY ARTERY DISEASE --ACUTE PHASE: ACUTE MYOCARDIAL INFARCTION AND PERCUTANEOUS CORONARY INTERVENTION

0289 Median time to ECG

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

0286 Aspirin at arrival [for patients being transferred]

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

0288 Fibrinolytic therapy received within 30 minutes of ED arrival and Median time to fibrinolysis [for patients being transferred]

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

0290 Median time to transfer to another facility for acute coronary intervention

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure

0132 Aspirin at arrival for acute myocardial infarction

______ I approve the measure currently specified
______ I disapprove the measure currently specified
______ I abstain from voting on this measure
0163 Primary PCI within 90 minutes of hospital arrival

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

0164 Fibrinolytic therapy received within 30 minutes of hospital arrival

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

0137 ACEI or ARB for left ventricular systolic dysfunction- acute myocardial infarction (AMI) patients

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

0355 Bilateral cardiac catheterization rate

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

964 Therapy with aspirin, P2Y12 inhibitor and statin at discharge

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

0133 PCI mortality (risk-adjusted)

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

ATRIAL FIBRILLATION

1524 Assessment of thromboembolic risk

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

1525 Chronic anticoagulation therapy

[ ] I approve the measure currently specified
[ ] I disapprove the measure currently specified
[ ] I abstain from voting on this measure

IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)

ELECTRONIC VOTING ONLY—VOTING CLOSES THURSDAY, October 20, 2011, at 6:00 pm ET
1522  ACE/ARB therapy at discharge for ICD implant patients with LVSD
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

1528  Beta blocker at discharge for ICD implant patients with a previous MI
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

1529  Beta blocker at discharge for ICD implant patients with LVSD
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

965  Patients with an ICD implant who receive prescriptions for all medications (ACE/ARB and beta blockers) for which they are eligible for at discharge
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

HEART FAILURE

0079  Heart failure: Left ventricular ejection fraction assessment
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

0081  Heart failure: ACEI or ARB therapy for left ventricular systolic dysfunction
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure

0083  Heart Failure: Beta-blocker therapy for left ventricular systolic dysfunction
______  I approve the measure currently specified
______  I disapprove the measure currently specified
______  I abstain from voting on this measure
ACEI or ARB for left ventricular systolic dysfunction – heart failure patients

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

Congestive heart failure (CHF) mortality rate

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

CHF admission

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

Controlling high blood pressure

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

Evaluation of left ventricular systolic dysfunction

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

Beta blocker prescribed at discharge

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

Aspirin prescribed at discharge for AMI

I approve the measure currently specified
I disapprove the measure currently specified
I abstain from voting on this measure

HYPERTENSION

RECOMMENDED FOR ENDORSEMENT WITH PLACEMENT IN RESERVE STATUS